Buyout Desk
Strategic

Eli Lilly to acquire Calytrix Bio for up to $1.5 billion

Privately held biotech Calytrix Bio is developing an early-stage antibody therapy for essential thrombocythemia and myelofibrosis; the upfront payment was not disclosed.

Target
Calytrix Bio
Buyer
Eli Lilly and Company
Value
up to $1.5 billion

Eli Lilly has agreed to acquire privately held biotechnology company Calytrix Bio in a cash transaction valued at up to $1.5 billion, according to an announcement by Calytrix on Monday. The deal includes an undisclosed upfront cash payment and additional payments tied to clinical development and regulatory milestones. No expected closing date was given.

Calytrix Bio's main development asset is an early-stage antibody therapy intended to treat essential thrombocythemia and myelofibrosis, two rare blood disorders involving abnormal blood cell production in the bone marrow. The announcement did not provide clinical efficacy results or a timetable for further studies, and Calytrix did not specify its milestones or their payment amounts.

The acquisition adds the investigational therapy to Lilly's oncology portfolio and represents a further investment outside the diabetes and obesity treatments that have driven the company's recent commercial growth.

Background

Business
Privately held biotechnology company developing an early-stage antibody therapy for rare blood disorders
Deal type
Strategic

Sources

Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.